{"id":"https://openalex.org/W4396997177","doi":"https://doi.org/10.1681/asn.20203110s16b","title":"Pharmacodynamic (PD) Profiling of Reloxaliase in Patients with Severe Hyperoxaluria","display_name":"Pharmacodynamic (PD) Profiling of Reloxaliase in Patients with Severe Hyperoxaluria","publication_year":2020,"publication_date":"2020-10-01","ids":{"openalex":"https://openalex.org/W4396997177","doi":"https://doi.org/10.1681/asn.20203110s16b"},"language":"en","primary_location":{"id":"doi:10.1681/asn.20203110s16b","doi":"https://doi.org/10.1681/asn.20203110s16b","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1681/asn.20203110s16b","pdf_url":null,"source":{"id":"https://openalex.org/S115693375","display_name":"Journal of the American Society of Nephrology","issn_l":"1046-6673","issn":["1046-6673","1533-3450"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315620","host_organization_name":"American Society of Nephrology","host_organization_lineage":["https://openalex.org/P4310315620"],"host_organization_lineage_names":["American Society of Nephrology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Society of Nephrology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001244964","display_name":"Felix Knauf","orcid":"https://orcid.org/0000-0001-5762-1404","observed_orcids":["https://orcid.org/0000-0001-5762-1404"]},"institutions":[{"id":"https://openalex.org/I7877124","display_name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","ror":"https://ror.org/001w7jn25","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I7877124"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Felix Knauf","raw_affiliation_strings":["Allena Pharmaceuticals, Newton, MA;","University Hospital Charite, Berlin, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allena Pharmaceuticals, Newton, MA;","institution_ids":[]},{"raw_affiliation_string":"University Hospital Charite, Berlin, Germany;","institution_ids":["https://openalex.org/I7877124"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071597181","display_name":"Danica Gruji\u0107","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Danica Grujic","raw_affiliation_strings":["Allena Pharmaceuticals, Newton, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allena Pharmaceuticals, Newton, MA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028809698","display_name":"Mira T. Keddis","orcid":"https://orcid.org/0000-0001-8249-0848","observed_orcids":["https://orcid.org/0000-0001-8249-0848"]},"institutions":[{"id":"https://openalex.org/I4210127938","display_name":"Mayo Clinic Hospital","ror":"https://ror.org/03660jn93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099","https://openalex.org/I4210127938"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mira T. Keddis","raw_affiliation_strings":["Mayo Clinic Hospital, Phoenix, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Hospital, Phoenix, AZ","institution_ids":["https://openalex.org/I4210127938"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001704439","display_name":"Alicia M. Weeks","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alicia Weeks","raw_affiliation_strings":["Allena Pharmaceuticals, Newton, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allena Pharmaceuticals, Newton, MA;","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5105885788","display_name":"Annamaria T. Kausz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Annamaria T. Kausz","raw_affiliation_strings":["Allena Pharmaceuticals, Newton, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allena Pharmaceuticals, Newton, MA;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"10S","first_page":"6","last_page":"6"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10606","display_name":"Kidney Stones and Urolithiasis Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10606","display_name":"Kidney Stones and Urolithiasis Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10516","display_name":"Parathyroid Disorders and Treatments","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11139","display_name":"Gout, Hyperuricemia, Uric Acid","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hyperoxaluria","display_name":"hyperoxaluria","score":0.8539999723434448},{"id":"https://openalex.org/keywords/enteric-hyperoxaluria","display_name":"enteric hyperoxaluria","score":0.9179999828338623},{"id":"https://openalex.org/keywords/primary-hyperoxaluria","display_name":"primary hyperoxaluria","score":0.996999979019165},{"id":"https://openalex.org/keywords/oxalate-decarboxylase","display_name":"oxalate decarboxylase","score":0.9010000228881836},{"id":"https://openalex.org/keywords/plasma-oxalate","display_name":"plasma oxalate","score":0.8169999718666077},{"id":"https://openalex.org/keywords/urinary-oxalate","display_name":"urinary oxalate","score":0.9829999804496765},{"id":"https://openalex.org/keywords/formate-accumulation","display_name":"formate accumulation","score":0.7490000128746033},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7080000042915344},{"id":"https://openalex.org/keywords/oral-enzyme-therapy","display_name":"oral enzyme therapy","score":0.7210000157356262},{"id":"https://openalex.org/keywords/chronic-kidney-disease","display_name":"chronic kidney disease","score":0.7559999823570251},{"id":"https://openalex.org/keywords/oxalosis","display_name":"oxalosis","score":0.7480000257492065},{"id":"https://openalex.org/keywords/drug-absorption","display_name":"drug absorption","score":0.722000002861023},{"id":"https://openalex.org/keywords/gastrointestinal-tolerability","display_name":"gastrointestinal tolerance","score":0.609000027179718},{"id":"https://openalex.org/keywords/oxalate-degradation","display_name":"oxalate degradation","score":0.5720000267028809},{"id":"https://openalex.org/keywords/end-stage-renal-disease-prevention","display_name":"end-stage renal disease prevention","score":0.6349999904632568}],"concepts":[{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5771834850311279},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5251452922821045},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.4055190980434418},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3736211657524109},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37151509523391724},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.2301585078239441}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1681/asn.20203110s16b","doi":"https://doi.org/10.1681/asn.20203110s16b","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1681/asn.20203110s16b","pdf_url":null,"source":{"id":"https://openalex.org/S115693375","display_name":"Journal of the American Society of Nephrology","issn_l":"1046-6673","issn":["1046-6673","1533-3450"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315620","host_organization_name":"American Society of Nephrology","host_organization_lineage":["https://openalex.org/P4310315620"],"host_organization_lineage_names":["American Society of Nephrology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Society of Nephrology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3119547741","https://openalex.org/W4396998332","https://openalex.org/W4229071831","https://openalex.org/W3081536773","https://openalex.org/W3069189847","https://openalex.org/W4408165470","https://openalex.org/W2736262768","https://openalex.org/W2014529144","https://openalex.org/W4280579940","https://openalex.org/W2560388921"],"abstract_inverted_index":{"Background:":[0],"Hyperoxaluria":[1],"is":[2],"a":[3,43],"major":[4],"risk":[5],"factor":[6],"for":[7,247,282],"kidney":[8,15,20],"stones":[9],"and":[10,26,33,63,71,75,84,95,118,124,127,145,149,153,163,167,192,202,208,311],"can":[11],"lead":[12],"to":[13,39,51,278,328],"chronic":[14],"disease":[16],"(CKD).":[17],"With":[18],"decreasing":[19],"function,":[21],"plasma":[22,159],"oxalate":[23,27,45,53,65,93,99],"(POx)":[24],"rises":[25],"may":[28,58],"deposit":[29],"in":[30,67,196,276,308,313],"the":[31,55,61,80,102,240,245,251,262,291,298,305,385],"kidneys":[32],"other":[34],"tissues":[35],"(systemic":[36],"oxalosis)":[37],"leading":[38],"ESRD.":[40],"Reloxaliase":[41,258],"(REL),":[42],"non-absorbed,":[44],"specific":[46],"oral":[47],"enzyme":[48],"therapy":[49],"designed":[50],"degrade":[52],"along":[54],"GI":[56,180,292],"tract,":[57],"potentially":[59],"reduce":[60],"systemic":[62,96,283],"renal":[64],"burden":[66],"patients":[68],"with":[69,115,139,297,316],"enteric":[70],"primary":[72],"hyperoxaluria":[73],"(EH":[74],"PH).":[76],"This":[77,108,294],"study":[78,112],"tested":[79],"PD":[81],"of":[82,92,98,105,136,233,242,244,250,254,264,273,288,300,384],"REL,":[83,234],"addressed":[85],"questions":[86],"regarding":[87],"potential":[88,281],"formate":[89,215,265],"accumulation":[90,266],"(by-product":[91],"degradation)":[94],"absorption":[97,232],"decarboxilase":[100],"(OxDc,":[101],"active":[103],"component":[104],"REL).":[106],"Methods:":[107],"12-week,":[109],"open":[110],"label":[111],"enrolled":[113],"subjects":[114,315,376],"EH,":[116,189],"CKD":[117],"hyperoxalemia":[119],"(UOx":[120,129],"\u226540mg/d,":[121],"eGFR":[122,157,336],"<45mL/min":[123],"POx>5\u03bcmol/L,":[125],"n=10)":[126],"PH":[128,375],"\u226540":[130],"mg/d,":[131],"n=5)":[132],"who":[133],"received":[134],"7,500u":[135],"REL":[137,274],"5x/day":[138],"meals/snacks.":[140],"Parameters":[141],"assessed":[142],"at":[143,206,365],"baseline,":[144],"weeks":[146],"4,":[147],"8":[148],"12":[150],"included":[151],"POx":[152,191,203,310,343,377],"UOx":[154,193,198,312],"(only":[155],"if":[156,364],">15mL/min),":[158],"formic":[160],"acid":[161],"(pre-":[162],"post-prandial/post-dose;":[164],"Q2":[165],"Solutions)":[166],"OxDc":[168,248],"(specific":[169],"ELISA,":[170],"Absorption":[171],"Systems).":[172],"Results:":[173],"Reported":[174],"adverse":[175],"events":[176],"(AEs)":[177],"were":[178,183,220,238,371],"mostly":[179],"related;":[181],"there":[182,228],"no":[184,214,230],"related":[185],"serious":[186],"AEs.":[187],"In":[188],"both":[190,309],"decreased":[194],"substantially;":[195],"PH,":[197],"did":[199],"not":[200],"change,":[201],"stayed":[204],"normal":[205,224],"baseline":[207],"during":[209,369],"treatment":[210,370],"(Table).":[211],"There":[212],"was":[213,229,259,362,378],"accumulation,":[216],"as":[217,235,302],"all":[218,236],"samples":[219,237],"below":[221,239,381],"or":[222,380],"within":[223,290],"range":[225],"(1-9mg/L).":[226],"Similarly,":[227],"detectable":[231],"limit":[241,383],"detection":[243,382],"assay":[246,386],"(<0.0001%":[249],"administered":[252],"dose":[253],"37,500":[255],"u/day).":[256],"Conclusions:":[257],"well":[260],"tolerated;":[261],"absence":[263],"further":[267],"supports":[268],"its":[269,286],"safety.":[270],"The":[271],"lack":[272],"absorption,":[275],"addition":[277],"supporting":[279],"low":[280],"toxicity,":[284],"confirms":[285],"site":[287],"action":[289],"tract.":[293],"best":[295],"aligns":[296],"pathophysiology":[299],"EH":[301,314,332],"evidenced":[303],"by":[304],"substantial":[306],"reduction":[307],"CKD/ESRD.":[317],"Funding:":[318],"Commercial":[319],"Support":[320],"-":[321,324],"Allena":[322],"Pharmaceuticals":[323],"Change":[325],"from":[326],"Baseline":[327],"Weeks":[329],"4-121":[330],"AII":[331],"PH2":[333],"&":[334],"PH3":[335],"15-452":[337],"n=3":[338],"eGFR<15":[339],"n=7":[340],"eGFR>60":[341],"n=5":[342],"(umol/L)":[344],"Mean":[345,354],"(SD)":[346,355],"-28.7%":[347],"(18.6)":[348],"-29.2%":[349],"(30.2)":[350],"NA3":[351],"UOx/UCr":[352],"(mg/g)":[353],"-35.4%":[356],"(8.8)":[357],"NA":[358],"4.4%":[359],"(19.6)":[360],"1Mean":[361],"calculated":[363],"least":[366],"2/3":[367],"values":[368],"available2eGFR":[372],"(mL/min/1.73":[373],"m2)3In":[374],"normal,":[379]},"counts_by_year":[],"updated_date":"2026-10-22T18:32:59.640997","created_date":"2024-05-18T00:00:00"}